Overall survival was significantly longer in the necitumumab plus gemcitabine and cisplatin group than in the gemcitabine and cisplatin alone group ( median @ months -LSB- @ % CI @-@ -RSB- ) vs @ months -LSB- @-@ -RSB- ; stratified hazard ratio @ -LSB- @ % CI @-@ ; p = @ -RSB- ) .